{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000063","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.449898+00:00","generated_at":"2026-06-01T21:18:48.150605+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arvinas/Pfizer report updated Phase 1b combo data of vepdegestrant + palbociclib; consistent with prior","bullets":["Clinical benefit rate 63% across all doses; at RP3D 200 mg, CBR 67%; ORR 42% overall, 53% at 200 mg.","Median progression-free survival 11.2 months across doses; at 200 mg, mPFS 13.9 months (95% CI: 8.1-NR).","Median duration of response 14.6 months in 13 responders; safety consistent with prior, Grade 3/4 neutropenia 91%.","ctDNA showed marked reduction in tumor fraction (-98.9%) after one cycle regardless of ESR1 mutation status."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000063","json":"https://secwatch.observer/filing/0001655759-24-000063.json","markdown":"https://secwatch.observer/filing/0001655759-24-000063.md","text":"https://secwatch.observer/filing/0001655759-24-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000063/0001655759-24-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000063/arvn-20240516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:18:48.150605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}